Abstract
Inhibitors of p38 MAP kinases show promise for the treatment of inflammatory and immunological disorders and some cancers. There is a substantial body of experimental evidence across several organ systems suggesting that p38 also mediates developmental, differentiation and proliferation processes. As a consequence of the wide-ranging regulatory role of p38 kinase in diverse cellular processes, the possibility of adverse events resulting from undesired pharmacological activity is a major concern for the p38 inhibitor drug class. Taking into consideration the limitations of experimental modeling systems, together the data may indicate that profound inhibition of p38 has the potential to impact these processes during fetal or neonatal development. The difficulty comes in extrapolating these findings to predict potential adverse effects under conditions of partial inhibition of p38 activity, and in an adult population in which these processes are typically only recapitulated during repair or adaptive responses. As such, the goal of this review of the targets of p38 activity is to bring an awareness of the those organ systems that should be monitored for potential toxicity, as well as to present a potential mechanistic basis for such monitoring or for investigation of adverse effects that may develop with administration of a p38 inhibitor.
Keywords: immunological disorders, pro-inflammatory cytokines, c-jun n-terminal (jnk), genetically-modified cell culture, type I interferon (ifn) receptor, extracellular signal-regulated kinases
Current Topics in Medicinal Chemistry
Title: Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Volume: 5 Issue: 10
Author(s): Donna M. Dambach
Affiliation:
Keywords: immunological disorders, pro-inflammatory cytokines, c-jun n-terminal (jnk), genetically-modified cell culture, type I interferon (ifn) receptor, extracellular signal-regulated kinases
Abstract: Inhibitors of p38 MAP kinases show promise for the treatment of inflammatory and immunological disorders and some cancers. There is a substantial body of experimental evidence across several organ systems suggesting that p38 also mediates developmental, differentiation and proliferation processes. As a consequence of the wide-ranging regulatory role of p38 kinase in diverse cellular processes, the possibility of adverse events resulting from undesired pharmacological activity is a major concern for the p38 inhibitor drug class. Taking into consideration the limitations of experimental modeling systems, together the data may indicate that profound inhibition of p38 has the potential to impact these processes during fetal or neonatal development. The difficulty comes in extrapolating these findings to predict potential adverse effects under conditions of partial inhibition of p38 activity, and in an adult population in which these processes are typically only recapitulated during repair or adaptive responses. As such, the goal of this review of the targets of p38 activity is to bring an awareness of the those organ systems that should be monitored for potential toxicity, as well as to present a potential mechanistic basis for such monitoring or for investigation of adverse effects that may develop with administration of a p38 inhibitor.
Export Options
About this article
Cite this article as:
Dambach M. Donna, Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases, Current Topics in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/1568026054985911
DOI https://dx.doi.org/10.2174/1568026054985911 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Arterial Dilatation-Related Diseases: The Prerequisite Condition of Arterial Elastic Tissue Damage and Endovascular Treatment
Recent Patents on Medical Imaging Advanced Echocardiographic Imaging of the Congenitally Malformed Heart
Current Cardiology Reviews Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Taking a Systems Approach to the Identification of Novel Therapeutic Targets and Biomarkers
Current Pharmaceutical Biotechnology Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Vascular Arginase and Hypertension
Current Hypertension Reviews Issues and Progress in Isolation of Susceptibility Genes of Essential Hypertension
Current Hypertension Reviews Variations and Abnormalities of Major Thoracic Vascular Structures
Current Medical Imaging Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy 3D Printing in Modern Cardiology
Current Pharmaceutical Design The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets The Role of Zebrafish in Chemical Genetics
Current Medicinal Chemistry Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry